Skip to main content
Caplight Logo









Windward Bio

Windward Bio

Private
BaselHealthcare & Life Scienceshttps://windwardbio.com/

Last Round

VC Round

May 4, 2026

Total Funding Raised

$200M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Windward Bio is a biotechnology company that develops long-acting antibody therapies for immunological, respiratory, and dermatological diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B2C

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

long-acting antibodiesmonoclonal antibodymAbTSLP inhibitorextended-dosing biologicsimmunologybiopharmabispecific antibodyclinical-stage biotechasthma therapyCOPD therapybiologicsTSLP x IL-13 bispecificdrug in-licensingsubcutaneous injectiondermatology therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Windward Bio Comparables

Compare Windward Bio with similar companies based on industry and business-model similarity.

Windward Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
GSK plc
80%
Biosion, Inc.
56%
AirNexis Therapeutics
54%

Windward Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundMay 4, 2026
Series AJan 10, 2025

Key People

Founding team and executive leadership

Luca Santarelli

Founder, CEO And Chairman

Founding Team

Teit Agger

Chief Technology Officer

Executive Team

Claudia D'Augusta

Group CFO

Executive Team

Windward Bio Investors

Notable investors and investment history

Windward Bio investors
InvestorRounds
Janus Henderson GroupVC Round
RA Capital ManagementVC Round
Omega FundsVC Round, Series A
Blue Owl CapitalVC Round
OrbiMedVC Round, Series A
Novo HoldingsVC Round, Series A
Sanofi VenturesVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors grew 71% MoM, reaching 2.5K.

  • Jul 16, 2026

    Grew 23% QoQ, from 40 to 49 employees.

Windward Bio Filings

Explore SEC and related filing metadata, where available.

Windward Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Windward Bio's valuation, stock price, and market status.

Is Windward Bio a public or private company?

Windward Bio is a private company.

What is the current stock price of Windward Bio?

Windward Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Windward Bio worth (valuation)?

Valuation information for Windward Bio is not publicly available.

Can I buy Windward Bio stock?

Windward Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Windward Bio's last funding round?

Windward Bio's most recent funding round was Growth Equity on May 4, 2026.

Who are the main investors in Windward Bio?

Key investors in Windward Bio include OrbiMed.

Will Windward Bio IPO soon?

No public IPO plans have been announced for Windward Bio.

How can I track Windward Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Windward Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBasel
Employee Range36
Year Founded2024
Last FundingMay 4, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?